HomeFileStructural heart disease

Structural heart disease

Balloon-Expandable Valve Outdoes Itself

The objective of this paper recently published in J Am Coll Cardiol Intv was to compare the...

AHA 2020 | Post-TAVR Anticoagulation in Patients with Atrial Fibrillation

Direct anticoagulant agents were associated with lower long-term mortality in patients with atrial fibrillation discharged after successful...

AHA 2020 | Rise in Early Discharge After TAVR Has the Expected Cost

As hospitalization time after a transcatheter aortic valve replacement (TAVR) is reduced, we are observing a concomitant...

Asymptomatic Severe Aortic Stenosis, When Should We Intervene?

Data from recent observational randomized studies suggest that most patients with asymptomatic severe aortic stenosis will eventually...

Conscious Versus General Anesthesia in TAVR

Patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) can safely undergo the procedure under...

TCT 2020 | TAVR Appears to Be the Solution for All Dysfunctional Biological Valves

Transcatheter aortic valve replacement (TAVR) results durable at 5 years to treat failed surgical bioprosthetic valves and...

TCT 2020 | Surprising Differences in Stroke between SAPIEN 3 and Evolut R

One-year outcomes of the head to head trial between CoreValve Evolut R vs Sapien 3 showed a...

TCT 2020 | Efficacy of Cerebral Protection Device TriGUARD 3 During TAVR

Cerebral protection device TriGUARD 3, designed to cover all supra-aortic vessels during transcatheter aortic valve replacement (TAVR), is...